» Articles » PMID: 37251735

Comparison of Extracellular Vesicle Isolation Processes for Therapeutic Applications

Overview
Journal J Tissue Eng
Date 2023 May 30
PMID 37251735
Authors
Affiliations
Soon will be listed here.
Abstract

While extracellular vesicles (EVs) continue to gain interest for therapeutic applications, their clinical translation is limited by a lack of optimal isolation methods. We sought to determine how universally applied isolation methods impact EV purity and yield. EVs were isolated by ultracentrifugation (UC), polyethylene glycol precipitation, Total Exosome Isolation Reagent, an aqueous two-phase system with and without repeat washes or size exclusion chromatography (SEC). EV-like particles could be detected for all isolation methods but varied in their purity and relative expression of surface markers (Alix, Annexin A2, CD9, CD63 and CD81). Assessments of sample purity were dependent on the specificity of characterisation method applied, with total particle counts and particle to protein (PtP) ratios often not aligning with quantitative measures of tetraspanin surface markers obtained using high-resolution nano-flow cytometry. While SEC resulted in the isolation of fewer particles with a relatively low PtP ratio (1.12 × 10 ± 1.43 × 10 vs highest recorded; ATPS/R 2.01 × 10 ± 1.15 × 10,  ⩽ 0.05), EVs isolated using this method displayed a comparatively high level of tetraspanin positivity (e.g. ExoELISA CD63⁺ particles; 1.36 × 10  1.18 × 10 vs ATPS/R 2.58 × 10  1.92 × 10,  ⩽ 0.001). Results originating from an accompanying survey designed to evaluate pragmatic considerations surrounding method implementation (e.g. scalability and cost) identified that SEC and UC were favoured for overall efficiency. However, reservations were highlighted in the scalability of these methods, which could potentially hinder downstream therapeutic applications. In conclusion, variations in sample purity and yield were evident between isolation methods, while standard non-specific assessments of sample purity did not align with advanced quantitative high-resolution analysis of EV surface markers. Reproducible and specific assessments of EV purity will be critical for informing therapeutic studies.

Citing Articles

Extracellular Vesicles as Tools for Crossing the Blood-Brain Barrier to Treat Lysosomal Storage Diseases.

Lerussi G, Villagrasa-Araya V, Molto-Abad M, Del Toro M, Pintos-Morell G, Seras-Franzoso J Life (Basel). 2025; 15(1).

PMID: 39860010 PMC: 11766495. DOI: 10.3390/life15010070.


Characterization of extracellular vesicles by capillary zone electrophoresis: A novel concept for characterization of a next-generation drug delivery platform.

Stec A, Heinz A, Dziomba S J Pharm Anal. 2025; 14(12):101004.

PMID: 39802401 PMC: 11721263. DOI: 10.1016/j.jpha.2024.101004.


Interkingdom Communication via Extracellular Vesicles: Unraveling Plant and Pathogen Interactions and Its Potential for Next-Generation Crop Protection.

Li F, Lu Y, Xi K, Li Y, Chen X, Wang P Microorganisms. 2025; 12(12.

PMID: 39770594 PMC: 11677615. DOI: 10.3390/microorganisms12122392.


A machine learning model revealed that exosome small RNAs may participate in the development of breast cancer through the chemokine signaling pathway.

Mo J, Li X, Lei L, Peng J, Liang X, Zhou H BMC Cancer. 2024; 24(1):1435.

PMID: 39574053 PMC: 11580650. DOI: 10.1186/s12885-024-13173-x.


A comprehensive review of challenges and advances in exosome-based drug delivery systems.

Palakurthi S, Shah B, Kapre S, Charbe N, Immanuel S, Pasham S Nanoscale Adv. 2024; .

PMID: 39484149 PMC: 11523810. DOI: 10.1039/d4na00501e.